R&D channel feed

That BLA lit­tle Am­pio promised? That’s not go­ing any­where as FDA slap-down trig­gers an ug­ly rout

7 years ago

Paratek clears one last big hur­dle on the way to an FDA mar­ket­ing de­ci­sion for an­tibi­ot­ic

7 years ago

Re­genxBio ral­ly fades fast af­ter biotech re­ports set­backs, hos­pi­tal­iza­tion in gene ther­a­py study

7 years ago

First-in-hu­man stud­ies in sight, SQZ's cell ther­a­py tech wins over a di­verse group of in­vestors in $72M round

7 years ago
Discovery

14-year-old par­tial hold comes back to haunt Gem­phire, bat­ter­ing shares and wreck­ing time­lines

7 years ago
Pharma

PAH ther­a­py tanks in Phase III, oblit­er­at­ing Bellerophon's stock

7 years ago

Spark takes a beat­ing as he­mo­phil­ia safe­ty set­backs tor­pe­do stock, bur­nish ri­val Bio­Marin

7 years ago

Boehringer or­ga­nizes a coali­tion in search of first CF gene ther­a­py, work­ing with re­search, man­u­fac­tur­ing part­ners

7 years ago
Pharma

Who are the most pro­duc­tive drug de­vel­op­ers in bio­phar­ma? Our top-20 list has lots of sur­pris­es

7 years ago
Special

No sur­prise: FDA hands Pain Ther­a­peu­tics an­oth­er slap­down on Re­moxy, forc­ing a quick re­struc­tur­ing

7 years ago

Ovid's snap­shot of broad ef­fi­ca­cy da­ta for their PhII An­gel­man syn­drome tri­al can't stop a rout -- shares crushed

7 years ago

Clo­vis writes a $20 mil­lion check payable to the SEC, hop­ing to rid it­self of the lin­ger­ing ro­ci probe

7 years ago

Celtaxsys spins 'clin­i­cal­ly mean­ing­ful' da­ta on an­oth­er failed PhII cys­tic fi­bro­sis study

7 years ago

As a new study spot­lights a grow­ing role for LRRK2 in Parkin­son’s, De­nali clears an ear­ly tri­al hur­dle

7 years ago

Epizyme dis­cards a failed pro­gram for tazeme­to­stat as ex­ecs work to get an FDA hold lift­ed -- shares crater

7 years ago

No­var­tis dis­patch­es two more can­cer drug castoffs to a part­ner in Chi­na

7 years ago
Pharma

Game change: Pfiz­er dou­bles down on its late-stage pipeline as CEO Read dis­avows a long re­liance on M&A deals

7 years ago
Deals

Ham­mered by a se­ries of set­backs, NewLink ax­es staff (again) and cir­cles its wag­ons around trou­bled IDO pro­gram

7 years ago

Top 10: Takeda's late-stage pipeline will re­ly heav­i­ly on Shire drugs — but is it worth $62B?

7 years ago

Rev­enue shrink­ing, Sanofi sweeps a PhII can­cer ADC and TB vac­cine pro­gram out of the pipeline in Q2 cleanup

7 years ago

Ot­su­ka’s $886M-plus drug just flopped in its first cru­cial PhI­II tri­al for front­line AML

7 years ago

Te­va’s one-time block­buster-to-be — and now re­cur­ring em­bar­rass­ment — laquin­i­mod fails yet again, this time for Hunt­ing­ton’s

7 years ago

We've sched­uled your Type T meet­ing with FDA com­mish Scott Got­tlieb, where you can learn the art of rapid fire R&D

7 years ago
Pharma

Si­en­na con­cedes fail­ure in piv­otal ac­ne tri­al — will the laser-man­aged ther­a­py work in hair re­duc­tion?

7 years ago
First page Previous page 265266267268269270271 Next page Last page
A service from the Financial Times